A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." ...
Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...
Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.
A new study has identified the protein ADAMTS5 as playing a crucial role in the spread of ovarian cancer cells, offering a ...
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...
University of Kentucky Markey Cancer Center researchers presented promising results from an early-stage clinical trial ...
Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...
The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, ...
A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback